United Therapeutics Corporation (UTHR)

Market Cap	15.38B
Revenue (ttm)	2.62B
Net Income (ttm)	1.07B
Shares Out	44.49M
EPS (ttm)	21.73
PE Ratio	15.90
Forward PE	11.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,800
Open	349.76
Previous Close	350.01
Day's Range	345.33 - 351.63
52-Week Range	208.62 - 366.08
Beta	0.57
Analysts	Buy
Price Target	351.64 (+1.74%)
Earnings Date	Oct 30, 2024

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,168
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2023, UTHR's revenue was $2.33 billion, an increase of 20.20% compared to the previous year's $1.94 billion. Earnings were $984.80 million, an increase of 35.40%.

Analyst Forecast

According to 12 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $351.64, which is an increase of 1.74% from the latest price.

Price Target

$351.64

(1.74% upside)

Analyst Consensus: Buy